Natco Pharma Share Price
Sector: Biotechnology & Drugs
885.00 -4.65 (-0.52%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
862.60
Today’s High
895.35
52 Week Low
660.05
52 Week High
1638.35
884.15 -5.10 (-0.57%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
862.55
Today’s High
895.45
52 Week Low
726.80
52 Week High
1639.00
Key Metrics
- Market Cap (In Cr) 15851.22
- Beta 0.75
- Div. Yield (%) 0.67
- P/B 2.72
- TTM P/E 13.32
- Peg Ratio 0.18
- Sector P/E 26.62
- Open Price 883.1
- Prev Close 889.65
Natco Pharma Analysis
Price Analysis
-
1 Week7.45%
-
3 Months-29.24%
-
6 Month-31.17%
-
YTD-35.9%
-
1 Year-12.92%
Risk Meter
- 52% Low risk
- 52% Moderate risk
- 52% Balanced Risk
- 52% High risk
- 52% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 3
- 3
- 3
- 2
- Hold
- 1
- 1
- 1
- 2
- Sell
- 2
- 2
- 2
- 2
- Strong Sell
- 0.00
- 0.00
- 0.00
- 1
- Total
- 7
- 7
- 7
- 8
Natco Pharma News
Eli Lilly launches its blockbuster weight loss drug Mounjaro in India
3 min read . 21 Mar 2025Over 175 small-caps face double-digit losses in Feb amid worst crash since Covid
3 min read . 03 Mar 2025Natco Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 3998.8
- Selling/ General/ Admin Expenses Total
- 1227
- Depreciation/ Amortization
- 186.8
- Other Operating Expenses Total
- 30.9
- Total Operating Expense
- 2431.4
- Operating Income
- 1567.4
- Net Income Before Taxes
- 1673.5
- Net Income
- 1388.3
- Diluted Normalized EPS
- 77.42
- Period
- 2024
- Total Assets
- 6906.3
- Total Liabilities
- 1053.2
- Total Equity
- 5853.1
- Tangible Book Valueper Share Common Eq
- 316.01
- Period
- 2024
- Cashfrom Operating Activities
- 1211.6
- Cashfrom Investing Activities
- -1032.7
- Cashfrom Financing Activities
- -246.9
- Net Changein Cash
- -61.5
- Period
- 2023
- Total Revenue
- 2707.1
- Selling/ General/ Admin Expenses Total
- 914.3
- Depreciation/ Amortization
- 163.8
- Other Operating Expenses Total
- 11.4
- Total Operating Expense
- 1930.1
- Operating Income
- 777
- Net Income Before Taxes
- 861.9
- Net Income
- 715.3
- Diluted Normalized EPS
- 38.48
- Period
- 2023
- Total Assets
- 5657.4
- Total Liabilities
- 783.6
- Total Equity
- 4873.8
- Tangible Book Valueper Share Common Eq
- 256.81
- Period
- 2023
- Cashfrom Operating Activities
- 849.1
- Cashfrom Investing Activities
- -477.1
- Cashfrom Financing Activities
- -363
- Net Changein Cash
- 20.8
- Period
- 2022
- Total Revenue
- 1944.8
- Selling/ General/ Admin Expenses Total
- 819.2
- Depreciation/ Amortization
- 142.6
- Other Operating Expenses Total
- 17.2
- Total Operating Expense
- 1823.9
- Operating Income
- 120.9
- Net Income Before Taxes
- 202.2
- Net Income
- 170
- Diluted Normalized EPS
- 7.35
- Period
- 2022
- Total Assets
- 5109.1
- Total Liabilities
- 845.5
- Total Equity
- 4263.6
- Tangible Book Valueper Share Common Eq
- 226.31
- Period
- 2022
- Cashfrom Operating Activities
- 46.5
- Cashfrom Investing Activities
- -5.3
- Cashfrom Financing Activities
- 34.8
- Net Changein Cash
- 85.3
- Period
- 2021
- Total Revenue
- 2052.1
- Selling/ General/ Admin Expenses Total
- 803.1
- Depreciation/ Amortization
- 116.9
- Other Operating Expenses Total
- 11.8
- Total Operating Expense
- 1562.8
- Operating Income
- 489.3
- Net Income Before Taxes
- 579.6
- Net Income
- 440.9
- Diluted Normalized EPS
- 22.82
- Period
- 2021
- Total Assets
- 4791.9
- Total Liabilities
- 670.3
- Total Equity
- 4121.6
- Tangible Book Valueper Share Common Eq
- 225.53
- Period
- 2021
- Cashfrom Operating Activities
- 298.8
- Cashfrom Investing Activities
- -103.3
- Cashfrom Financing Activities
- -185.7
- Net Changein Cash
- 6
- Period
- 2020
- Total Revenue
- 1915
- Selling/ General/ Admin Expenses Total
- 746.7
- Depreciation/ Amortization
- 99.8
- Other Operating Expenses Total
- 23.5
- Total Operating Expense
- 1432.2
- Operating Income
- 482.8
- Net Income Before Taxes
- 568.7
- Net Income
- 460.8
- Diluted Normalized EPS
- 24.54
- Period
- 2020
- Total Assets
- 4587.8
- Total Liabilities
- 814.3
- Total Equity
- 3773.5
- Tangible Book Valueper Share Common Eq
- 206.77
- Period
- 2020
- Cashfrom Operating Activities
- 417.3
- Cashfrom Investing Activities
- -167
- Cashfrom Financing Activities
- -250.8
- Net Changein Cash
- -8.5
- Period
- 2019
- Total Revenue
- 2094.5
- Selling/ General/ Admin Expenses Total
- 741.4
- Depreciation/ Amortization
- 81
- Other Operating Expenses Total
- 10.1
- Total Operating Expense
- 1378.5
- Operating Income
- 716
- Net Income Before Taxes
- 824.7
- Net Income
- 644.4
- Diluted Normalized EPS
- 34.31
- Period
- 2019
- Total Assets
- 4303.1
- Total Liabilities
- 814.1
- Total Equity
- 3489
- Tangible Book Valueper Share Common Eq
- 190.44
- Period
- 2019
- Cashfrom Operating Activities
- 668.8
- Cashfrom Investing Activities
- -612.2
- Cashfrom Financing Activities
- -50.9
- Net Changein Cash
- 6.6
- Period
- 2018
- Total Revenue
- 2202
- Selling/ General/ Admin Expenses Total
- 730.2
- Depreciation/ Amortization
- 66.2
- Other Operating Expenses Total
- 8.4
- Total Operating Expense
- 1339.8
- Operating Income
- 862.2
- Net Income Before Taxes
- 887.2
- Net Income
- 696.2
- Diluted Normalized EPS
- 38.67
- Period
- 2018
- Total Assets
- 3715.1
- Total Liabilities
- 642.9
- Total Equity
- 3072.2
- Tangible Book Valueper Share Common Eq
- 166.2
- Period
- 2018
- Cashfrom Operating Activities
- 463.6
- Cashfrom Investing Activities
- -1115.5
- Cashfrom Financing Activities
- 650.9
- Net Changein Cash
- -1.8
- Period
- 2024-12-31
- Total Revenue
- 474.8
- Selling/ General/ Admin Expenses Total
- 141.6
- Depreciation/ Amortization
- 47
- Other Operating Expenses Total
- 211.6
- Total Operating Expense
- 483
- Operating Income
- -8.2
- Net Income Before Taxes
- 163.7
- Net Income
- 133
- Diluted Normalized EPS
- 7.43
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 1371.1
- Selling/ General/ Admin Expenses Total
- 151.5
- Depreciation/ Amortization
- 45.8
- Other Operating Expenses Total
- 237.7
- Total Operating Expense
- 612.6
- Operating Income
- 758.5
- Net Income Before Taxes
- 818.2
- Net Income
- 677.3
- Diluted Normalized EPS
- 37.81
- Period
- 2024-09-30
- Total Assets
- 8244.7
- Total Liabilities
- 1094.8
- Total Equity
- 7149.9
- Tangible Book Valueper Share Common Eq
- 385.93
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1137
- Cashfrom Investing Activities
- -881.7
- Cashfrom Financing Activities
- -219.1
- Net Changein Cash
- 34.2
- Period
- 2024-06-30
- Total Revenue
- 1362.6
- Selling/ General/ Admin Expenses Total
- 142
- Depreciation/ Amortization
- 44.1
- Other Operating Expenses Total
- 235.6
- Total Operating Expense
- 601.9
- Operating Income
- 760.7
- Net Income Before Taxes
- 803.6
- Net Income
- 668.5
- Diluted Normalized EPS
- 37.32
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1068.3
- Selling/ General/ Admin Expenses Total
- 142.5
- Depreciation/ Amortization
- 55.5
- Other Operating Expenses Total
- 285.9
- Total Operating Expense
- 626.5
- Operating Income
- 441.8
- Net Income Before Taxes
- 477.6
- Net Income
- 386.3
- Diluted Normalized EPS
- 21.57
- Period
- 2024-03-31
- Total Assets
- 6906.3
- Total Liabilities
- 1053.2
- Total Equity
- 5853.1
- Tangible Book Valueper Share Common Eq
- 316.01
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1211.6
- Cashfrom Investing Activities
- -1032.7
- Cashfrom Financing Activities
- -246.9
- Net Changein Cash
- -61.5
- Period
- 2023-12-31
- Total Revenue
- 758.6
- Selling/ General/ Admin Expenses Total
- 121.9
- Depreciation/ Amortization
- 44.2
- Other Operating Expenses Total
- 206.4
- Total Operating Expense
- 534.7
- Operating Income
- 223.9
- Net Income Before Taxes
- 256.3
- Net Income
- 212.7
- Diluted Normalized EPS
- 11.88
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 1031.4
- Selling/ General/ Admin Expenses Total
- 122.4
- Depreciation/ Amortization
- 43.6
- Other Operating Expenses Total
- 235.2
- Total Operating Expense
- 617
- Operating Income
- 414.4
- Net Income Before Taxes
- 439.6
- Net Income
- 369
- Diluted Normalized EPS
- 20.6
- Period
- 2023-09-30
- Total Assets
- 6254
- Total Liabilities
- 960.5
- Total Equity
- 5293.5
- Tangible Book Valueper Share Common Eq
- 284.47
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 632.3
- Cashfrom Investing Activities
- -347.8
- Cashfrom Financing Activities
- -314.4
- Net Changein Cash
- -27.9
- Period
- 2023-06-30
- Total Revenue
- 1140.5
- Selling/ General/ Admin Expenses Total
- 138.2
- Depreciation/ Amortization
- 43.5
- Other Operating Expenses Total
- 278.3
- Total Operating Expense
- 656
- Operating Income
- 484.5
- Net Income Before Taxes
- 500
- Net Income
- 420.3
- Diluted Normalized EPS
- 23.26
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 897.9
- Selling/ General/ Admin Expenses Total
- 118.9
- Depreciation/ Amortization
- 41
- Other Operating Expenses Total
- 181.5
- Total Operating Expense
- 599.8
- Operating Income
- 298.1
- Net Income Before Taxes
- 324.4
- Net Income
- 275.8
- Diluted Normalized EPS
- 15.1
- Period
- 2023-03-31
- Total Assets
- 5657.4
- Total Liabilities
- 783.6
- Total Equity
- 4873.8
- Tangible Book Valueper Share Common Eq
- 256.81
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 849.1
- Cashfrom Investing Activities
- -477.1
- Cashfrom Financing Activities
- -363
- Net Changein Cash
- 20.8
- Period
- 2022-12-31
- Total Revenue
- 492.5
- Selling/ General/ Admin Expenses Total
- 105.6
- Depreciation/ Amortization
- 41.5
- Other Operating Expenses Total
- 165.6
- Total Operating Expense
- 428.1
- Operating Income
- 64.4
- Net Income Before Taxes
- 81.4
- Net Income
- 62.3
- Diluted Normalized EPS
- 3.41
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Natco Pharma Technical
Moving Average
SMA
- 5 Day861.37
- 10 Day828.77
- 20 Day816.82
- 50 Day854.42
- 100 Day1092.68
- 300 Day1248.11
Natco Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Eris Lifesciences
- 1478.65
- 10.7
- 0.73
- 1593
- 815.5
- 20256.49
- Alembic Pharmaceuticals
- 872.95
- -2.5
- -0.29
- 1296.15
- 725.6
- 17070.26
- Natco Pharma
- 885
- -4.65
- -0.52
- 1638.35
- 660.05
- 15851.22
- Sanofi India
- 6060.55
- -217.9
- -3.47
- 7593.6
- 4145.9
- 13957.45
- Jubilant Pharmova
- 907.05
- -3.65
- -0.4
- 1309
- 616.85
- 14447.59
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Eris Lifesciences
- 50.75
- 7.72
- 20.71
- 24.96
- Alembic Pharmaceuticals
- 28.02
- 3.57
- 15.94
- 12.47
- Natco Pharma
- 11.49
- 2.72
- 14.63
- 25.16
- Sanofi India
- 42.4
- 16.79
- 32.83
- 21.53
- Jubilant Pharmova
- 96.94
- 2.65
- 6.15
- 5.13
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-Feb-25
- Quarterly Results & Interim Dividend
- 12-Nov-24
- Quarterly Results & Interim Dividend
- 12-Aug-24
- Quarterly Results & Interim Dividend
- 27-May-24
- Audited Results
- 14-Feb-24
- Quarterly Results & Interim Dividend
- 14-Nov-23
- Quarterly Results & Interim Dividend
- 09-Aug-23
- Quarterly Results & Interim Dividend
- 29-May-23
- Audited Results
- 08-Mar-23
- Buy Back of shares
- 09-Feb-23
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 28-Mar-24
- 22-Feb-24
- POM
- 29-Sept-23
- 05-Sept-23
- AGM
- 27-Mar-22
- 22-Feb-22
- POM
- -
- 12-Aug-24
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 12-Feb-25
- 18-Feb-25
- 18-Feb-25
- 1.5
- 12-Nov-24
- 27-Nov-24
- 27-Nov-24
- 1.5
- 12-Aug-24
- 23-Aug-24
- 23-Aug-24
- 3
- 14-Feb-24
- 26-Feb-24
- 26-Feb-24
- 1.25
- 15-Nov-23
- 24-Nov-23
- 24-Nov-23
- 1.25
- 09-Aug-23
- 22-Aug-23
- 22-Aug-23
- 7
- 09-Feb-23
- 21-Feb-23
- 21-Feb-23
- 1.25
- 10-Nov-22
- 22-Nov-22
- 21-Nov-22
- 0.75
- 10-Aug-22
- 22-Aug-22
- 19-Aug-22
- 3.5
- 14-Feb-22
- 25-Feb-22
- 24-Feb-22
- 2


